including pneumonia, sepsis and meningitis, and other chronic infections. [1] Novel antibiotics are the most favorable choice, however, the lack of innovative antibiotic development coupled with the frequent emergence of resistant strains may send us back to a preantibiotic era. Increasing evidence suggests that the excessive use of broad-spectrum antibiotics is associated with the risk of many metabolic and inflammatory diseases and some potential diseases related to the disruption of microbiota. [2][3] The rising prevalence of multidrug-resistant and highly virulent strains increases the urgent need for new therapies independent of antibacterial activity.S. aureus produces diverse exotoxins to facilitate its colonization and spreading during infection, and one of the most well-characterized exotoxins is Hla, a typical β-barrel pore-forming cytotoxin expressed by almost all clinical isolates. [4] Hla plays indispensable role in the pathogenesis of invasive infections, phagosome escape, and partially the triggering of the immune response. [5] Hla-induced activation of a disintegrin and metalloproteinase 10 is a critical mechanism of barrier disruption that greatly contributes to the pathogenesis of lethal S. aureus infections by enabling effective spreading. [6] Hla pore-dependent activation of NOD-like receptor protein 3 inflammasome is a successful example of pathogens exploiting host inflammatory signaling by enhancing the pathogenesis of severe S. aureus infection via inducing necrosis. [7] Moreover, Hla is exploited to manipulate adaptive immunity against S. aureus, suppressing the antigen-specific memory T cell response by disturbing DC-T cell crosstalk. [8] Notably, the pore formation activity of Hla is required for these cellular events as the inactive mutant H35L retains the ability to bind the membrane while impaired pore formation fails to act in these cases. The critical role of Hla in S. aureus pathogenesis renders it a developing therapeutic target for virulence-specific strategies aiming to attenuate the pathogenicity of S. aureus rather than directly kill bacteria.Host innate immune response is the first line of defense against S. aureus infection, promoting bacterial clearance and limiting the inciting injury of infection and systemic spreading through neutrophil chemotaxis, phagocytosis and inflammation. [9] However, inflammation is a double-edged sword. In most Antibiotic resistance is the greatest challenge for the treatment of Staphylococcus aureus (S. aureus) infection under the global antibiotic resistance crisis. With the bottleneck period of the development of new antibiotics, novel alternative agents are urgently in need. In this study, the small molecule amentoflavone is identified as a dual-action inhibitor of Hla, a pore-forming virulence determinant particularly important for S. aureus pathogenicity and Toll-like receptor 2 (TLR2) signaling, which triggers inflammation response upon recognizing pathogen-associated molecular patterns. Amentoflavone treatment conferred effective protec...